And now, I draw the line on this blog
5 years ago
As part of our ongoing response to media stories regarding autism and
vaccines, the AAP communications department is compiling a list of
parents who support the AAP and are available for interviews. We are
looking for two types of parents who could serve as spokespersons:
Parents of children with autism spectrum disorders who support
immunization and who do not believe there is any link between their
child's vaccines and his or her autism.
Parents of children who suffered a vaccine-preventable illness. This
could be a parent who declined immunization, whose child became ill
before a vaccine was available, or whose child was ineligible for
We are asking for your help identifying parents who would be good
spokespersons. They do not need to be expert public speakers. They
just need to be open with their story and interested in speaking out
on the issue. We will contact candidates in advance to conduct
pre-interviews, to offer guidance on talking to reporters and to
obtain a signed waiver giving us permission to release their name.
If a parent were placed on our list, we would offer their name and
contact information to select media. We hope to build a list of
parents from a wide range of geographical areas.
As the Jenny McCarthy and "Eli Stone" stories illustrate, this issue
is likely to recur in the national and local media. The AAP is
committed to doing all we can to counter such erroneous reports with
factual information supported by scientific evidence and AAP
The anti-vaccine groups often have emotional family stories on their
side. The ability to offer a reporter an interview with a similarly
compelling parent who is sympathetic to the AAP's goals is a powerful
tool for our media relations program.
Please contact me if you have any questions or to suggest a parent to interview.
Susan Stevens Martin
Director, Division of Media Relations
American Academy of Pediatrics
Information for Healthcare Professionals
Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics)
FDA ALERT [12/12/2007]: Dangerous or even fatal skin reactions (Stevens Johnson syndrome and toxic epidermal necrolysis), that can be caused by carbamazepine therapy, are significantly more common in patients with a particular human leukocyte antigen (HLA) allele, HLA-B*1502. This allele occurs almost exclusively in patients with ancestry across broad areas of Asia, including South Asian Indians. Genetic tests for HLA-B*1502 are already available. Patients with ancestry from areas in which HLA-B*1502 is present should be screened for the HLA-B*1502 allele before starting treatment with carbamazepine. If they test positive, carbamazepine should not be started unless the expected benefit clearly outweighs the increased risk of serious skin reactions. Patients who have been taking carbamazepine for more than a few months without developing skin reactions are at low risk of these events ever developing from carbamazepine. This is true for patients of any ethnicity or genotype, including patients positive for HLA-B*1502. This new safety information will be reflected in updated product labeling.
This information reflects FDA's current analysis of data available to FDA concerning this drug. FDA intends to update this when additional information or analyses become available.
Forty million to 50 million individuals in the United States now live with potentially disabling conditions. According to the Institute of Medicine (IOM), this number will likely increase substantially in coming decades. Aging baby boomers will fuel much of this growth as this enormous cohort enters age ranges with the greatest disease and disability risks. Although rates of some serious limitations among elderly individuals have declined, sobering reports warn of higher rates of potentially impairing conditions among children and working-age adults. ...
...As have others, we argue that devising strategies to confront disability must first start by defining disability. Definitions implicitly connote goals, which in turn suggest potential solutions and targets for action. When it comes to preventing or deterring disability, this definition matters.
Decades later, social changes upended medicalized notions of disability. Confluent forces, including the independent living movement, self-help initiatives, consumerism, deinstitutionalization, and civil rights campaigns for racial and ethnic minorities and women, catalyzed an incipient disability rights movement. By the 1970s, a new paradigm held that "problems lie not within the persons with disabilities but in the environment that fails to accommodate persons with disabilities and in the negative attitude of people without disabilities." Disability is "imposed on top of our impairments by the way we are unnecessarily isolated and excluded from full participation in society." This new "social" model of disability diverged importantly from medical model tenets. "The social model . . . views the issue mainly as a socially created problem and basically as a matter of the full integration of individuals into society. Disability is not an attribute of an individual, but rather a complex collection of conditions, many of which are created by the social environment." The issue is therefore an attitudinal or ideological one requiring social change, which at the political level becomes a question of human rights.
Explicitly recognizing the role of external forces (physical, social, and attitudinal) in precipitating or mitigating disability represents one of the major contributions of the ICF. Equally noteworthy, the ICF introduced participation in daily and community life as an explicit component of health. This concept shifted the emphasis from strict prevention to maximizing functioning and well-being—perspectives consonant with public health goals in an aging society. By presenting disability as a continuum, the ICF emphasized the universality of disability and stressed its "relevan[ce] to the lives of all people to different degrees and at different times in their lives."